MovDisordV3, Main, Merge, bibRecord, 006710

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Identifieur interne : 006710 ( Main/Merge ); précédent : 006709; suivant : 006711

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Auteurs : Ruth Djaldetti [Israël] ; Rivkah Inzelberg [Israël] ; Nir Giladi [Israël] ; Amos D. Korczyn [Israël] ; Yehudit Peretz-Aharon [Israël] ; Martin J. Rahey [Israël] ; Yuval Herishano [Israël] ; Silvia Honigman [Israël] ; Sami Badarny [Israël] ; Eldad Melamed [Israël]

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0309334

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Fluctuation, Motricité, Lévodopa, Antiparkinsonien, Voie orale, Forme soluble, Chimiothérapie, Traitement, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Fluctuations, Human, Levodopa, Motricity, Oral administration, Parkinson disease, Soluble form, Treatment.

Abstract

Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double-blind, levodopa-controlled, multicenter study of oral LDEE solution compared with standard levodopa-carbidopa (LD-CD) tablets. Sixty-two patients with Parkinson's disease who had "delayed on" and "no-on" subtypes of response fluctuations were randomly assigned for treatment with LDEE-CD or LD-CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post-lunch dose of LD were replaced. This was followed by a 2-week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post-lunch dose) in the LDEE-CD group. Percentage of no-on episodes after the post-lunch dose was decreased by 21% in the LDEE-CD group but increased by 36% in the LD-CD group (P < 0.01). In phase B, LDEE-CD decreased latencies to on after the morning and post-lunch doses and no-on episodes after the post-lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no-on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 002793
to stream PascalFrancis, to step Curation: 000528
to stream PascalFrancis, to step Checkpoint: 002671

Links to Exploration step

Pascal:02-0309334

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease</title>
<author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Rabin Medical Center</s1>
<s2>Petah Tiqva</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Petah Tiqva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hillel Yaffe Medical Center</s1>
<s2>Hadera</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Hillel Yaffe Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Sourasky Medical Center</s1>
<s2>Tel Aviv</s2>
<s3>ISR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Sourasky Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Sourasky Medical Center</s1>
<s2>Tel Aviv</s2>
<s3>ISR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Sourasky Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peretz Aharon, Yehudit" sort="Peretz Aharon, Yehudit" uniqKey="Peretz Aharon Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Rambam Medical Center</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Rambam Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rahey, Martin J" sort="Rahey, Martin J" uniqKey="Rahey M" first="Martin J." last="Rahey">Martin J. Rahey</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Assaf-Harofeh Hospital</s1>
<s2>Zerifin</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Assaf-Harofeh Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Soroka Medical Center</s1>
<s2>Beer Sheva</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Soroka Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>HaCarmel Hospital</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>HaCarmel Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>HaCarmel Hospital</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>HaCarmel Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Rabin Medical Center</s1>
<s2>Petah Tiqva</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Petah Tiqva</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0309334</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0309334 INIST</idno>
<idno type="RBID">Pascal:02-0309334</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002793</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000528</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002671</idno>
<idno type="wicri:doubleKey">0885-3185:2002:Djaldetti R:oral:solution:of</idno>
<idno type="wicri:Area/Main/Merge">006710</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease</title>
<author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Rabin Medical Center</s1>
<s2>Petah Tiqva</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Petah Tiqva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Hillel Yaffe Medical Center</s1>
<s2>Hadera</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Hillel Yaffe Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Sourasky Medical Center</s1>
<s2>Tel Aviv</s2>
<s3>ISR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Sourasky Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Sourasky Medical Center</s1>
<s2>Tel Aviv</s2>
<s3>ISR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Sourasky Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peretz Aharon, Yehudit" sort="Peretz Aharon, Yehudit" uniqKey="Peretz Aharon Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Rambam Medical Center</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Rambam Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rahey, Martin J" sort="Rahey, Martin J" uniqKey="Rahey M" first="Martin J." last="Rahey">Martin J. Rahey</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Assaf-Harofeh Hospital</s1>
<s2>Zerifin</s2>
<s3>ISR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Assaf-Harofeh Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Soroka Medical Center</s1>
<s2>Beer Sheva</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Soroka Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>HaCarmel Hospital</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>HaCarmel Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>HaCarmel Hospital</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>HaCarmel Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Rabin Medical Center</s1>
<s2>Petah Tiqva</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>Petah Tiqva</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Levodopa</term>
<term>Motricity</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Soluble form</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Fluctuation</term>
<term>Motricité</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Voie orale</term>
<term>Forme soluble</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double-blind, levodopa-controlled, multicenter study of oral LDEE solution compared with standard levodopa-carbidopa (LD-CD) tablets. Sixty-two patients with Parkinson's disease who had "delayed on" and "no-on" subtypes of response fluctuations were randomly assigned for treatment with LDEE-CD or LD-CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post-lunch dose of LD were replaced. This was followed by a 2-week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post-lunch dose) in the LDEE-CD group. Percentage of no-on episodes after the post-lunch dose was decreased by 21% in the LDEE-CD group but increased by 36% in the LD-CD group (P < 0.01). In phase B, LDEE-CD decreased latencies to on after the morning and post-lunch doses and no-on episodes after the post-lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no-on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption.</div>
</front>
</TEI>
<affiliations><list><country><li>Israël</li>
</country>
</list>
<tree><country name="Israël"><noRegion><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name>
</noRegion>
<name sortKey="Badarny, Sami" sort="Badarny, Sami" uniqKey="Badarny S" first="Sami" last="Badarny">Sami Badarny</name>
<name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
<name sortKey="Herishano, Yuval" sort="Herishano, Yuval" uniqKey="Herishano Y" first="Yuval" last="Herishano">Yuval Herishano</name>
<name sortKey="Honigman, Silvia" sort="Honigman, Silvia" uniqKey="Honigman S" first="Silvia" last="Honigman">Silvia Honigman</name>
<name sortKey="Inzelberg, Rivkah" sort="Inzelberg, Rivkah" uniqKey="Inzelberg R" first="Rivkah" last="Inzelberg">Rivkah Inzelberg</name>
<name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name>
<name sortKey="Peretz Aharon, Yehudit" sort="Peretz Aharon, Yehudit" uniqKey="Peretz Aharon Y" first="Yehudit" last="Peretz-Aharon">Yehudit Peretz-Aharon</name>
<name sortKey="Rahey, Martin J" sort="Rahey, Martin J" uniqKey="Rahey M" first="Martin J." last="Rahey">Martin J. Rahey</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006710 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006710 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:02-0309334
   |texte=   Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri